Enlicitide for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Enlicitide is an oral prescription medication for lowering cholesterol. Its strongest evidence concerns cholesterol reduction when existing treatment leaves cholesterol high. Enlicitide-specific prevention of cardiovascular events and lifespan extension remain unproven. Evidence comes mainly from one manufacturer-sponsored program. Daily administration and food timing matter; diarrhea and dizziness are possible burdens, pregnancy raises a theoretical concern, and rare or delayed harms remain poorly characterized. (Full Review)

Protocol

Daily dose
20 mg once daily
One tablet; higher-dose longevity regimens are not established.
Timing
Morning, empty stomach
At least 30 minutes before food or beverages other than water, black coffee, or plain tea.
Formulation
Swallowed whole
Without splitting, crushing, or chewing; absorption enhancer is part of the evaluated formulation.
Time to effect
Time to effect
By day 21
Near-maximal cholesterol lowering, sustained through day 56; not an event-prevention timeline.

Benefits

Contraindications
  • Pregnancy: Discontinuation when pregnancy is recognized unless benefits outweigh fetal risk.
Key Interactions
  • Food and beverages: Empty stomach; at least 30 minutes before food or beverages other than water, black coffee, or plain tea.
Theoretical (inferred from mechanism)
  • Other PCSK9 treatments: Evolocumab; incremental benefit and safety uncertain.
  • Lipid-lowering supplements: Red yeast rice; added cholesterol lowering is untested.
  • Over-the-counter binding products: High-dose fiber; effect on absorption or separation interval unknown.

Risk & Side Effects

  • High:
  • Medium: Diarrhea; dizziness
  • Low:
  • Speculative: Fetal or nursing-infant harm; rare or delayed adverse effects

Monitoring

Marker Target Why
LDL cholesterol No established target for enlicitide longevity use; track baseline change and individualized clinical goals Expected treatment response
Apolipoprotein B No established target for enlicitide longevity use; track change from baseline Expected particle-burden response
Non-HDL cholesterol No established target for enlicitide longevity use; track change from baseline Expected lipid response
Lipoprotein(a) No established enlicitide target; track baseline and change if elevated Expected secondary marker response
Triglycerides Not specified in the ER Context for fasting sampling

Cadence: Baseline; practical, nonvalidated lipid follow-up at 4–8 weeks, after material regimen changes, then every 3–6 months once stable. Symptoms during the first month and at each review.

Qualitative Assessment

  • Tolerability: Stool changes, dizziness, balance, and ability to exercise.
  • Adherence: Dosing, food timing, and missed doses.
  • Symptoms versus prevention: Better energy, sleep, or cognition is not an established efficacy endpoint; absence does not establish treatment failure.